AXDX vs. HLTH, TLIS, PRPO, OMIC, TBIO, RPID, PRE, BNGO, KALA, and NRXS Should you be buying Accelerate Diagnostics stock or one of its competitors? The main competitors of Accelerate Diagnostics include Cue Health (HLTH), Talis Biomedical (TLIS), Precipio (PRPO), Singular Genomics Systems (OMIC), Telesis Bio (TBIO), Rapid Micro Biosystems (RPID), Prenetics Global (PRE), Bionano Genomics (BNGO), KALA BIO (KALA), and NeurAxis (NRXS). These companies are all part of the "medical" sector.
Cue Health (NASDAQ:HLTH ) and Accelerate Diagnostics (NASDAQ:AXDX ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.
Accelerate Diagnostics has lower revenue, but higher earnings than Cue Health. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Cue Health, indicating that it is currently the more affordable of the two stocks.
Accelerate Diagnostics received 353 more outperform votes than Cue Health when rated by MarketBeat users. Likewise, 63.33% of users gave Accelerate Diagnostics an outperform vote while only 7.14% of users gave Cue Health an outperform vote.
45.5% of Cue Health shares are owned by institutional investors. Comparatively, 17.1% of Accelerate Diagnostics shares are owned by institutional investors. 12.5% of Cue Health shares are owned by insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Accelerate Diagnostics has a consensus target price of $1.00, indicating a potential upside of 13.38%. Given Cue Health's stronger consensus rating and higher probable upside, analysts clearly believe Accelerate Diagnostics is more favorable than Cue Health.
Cue Health has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.
In the previous week, Cue Health had 1 more articles in the media than Accelerate Diagnostics. MarketBeat recorded 3 mentions for Cue Health and 2 mentions for Accelerate Diagnostics. Cue Health's average media sentiment score of 0.34 beat Accelerate Diagnostics' score of -0.16 indicating that Accelerate Diagnostics is being referred to more favorably in the news media.
Accelerate Diagnostics has a net margin of -452.28% compared to Accelerate Diagnostics' net margin of -526.48%. Cue Health's return on equity of 0.00% beat Accelerate Diagnostics' return on equity.
Summary Accelerate Diagnostics beats Cue Health on 11 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding AXDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Accelerate Diagnostics Competitors List
Related Companies and Tools
